These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8468439)

  • 1. An update of recent moclobemide interaction data.
    Dingemanse J
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):167-80. PubMed ID: 8468439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline.
    Dingemanse J; Kneer J; Wallnöfer A; Kettler R; Zürcher G; Koulu M; Korn A
    Clin Neuropharmacol; 1996 Oct; 19(5):399-414. PubMed ID: 8889283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
    Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
    Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
    Zimmer R
    Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypertensive crises with reversible inhibitors of monoamine oxidases? Results of tyramine interaction studies].
    Bieck PR
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():25-31. PubMed ID: 2587674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.
    Sieradzan K; Channon S; Ramponi C; Stern GM; Lees AJ; Youdim MB
    J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):51S-59S. PubMed ID: 7593732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin syndrome with moclobemide-fluoxetine combination.
    Benazzi F
    Pharmacopsychiatry; 1996 Jul; 29(4):162. PubMed ID: 8858717
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.
    Mayersohn M; Guentert TW
    Clin Pharmacokinet; 1995 Nov; 29(5):292-332. PubMed ID: 8582117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine.
    Korn A; Da Prada M; Raffesberg W; Gasic S; Eichler HG
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):17-23. PubMed ID: 2450251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome".
    Dingemanse J; Wallnöfer A; Gieschke R; Guentert T; Amrein R
    Clin Pharmacol Ther; 1998 Apr; 63(4):403-13. PubMed ID: 9585794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moclobemide, a new reversible MAO inhibitor--interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients.
    Korn A; Eichler HG; Fischbach R; Gasic S
    Psychopharmacology (Berl); 1986; 88(2):153-7. PubMed ID: 3081926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline.
    Korn A; Wagner B; Moritz E; Dingemanse J
    Eur J Clin Pharmacol; 1996; 49(4):273-8. PubMed ID: 8857072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moclobemide. An update of its pharmacological properties and therapeutic use.
    Fulton B; Benfield P
    Drugs; 1996 Sep; 52(3):450-74. PubMed ID: 8875133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined SSRI-moclobemide treatment of psychiatric illness.
    Joffe RT; Bakish D
    J Clin Psychiatry; 1994 Jan; 55(1):24-5. PubMed ID: 8294388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine.
    Gieschke R; Schmid-Burgk W; Amrein R
    J Neural Transm Suppl; 1988; 26():97-104. PubMed ID: 3283292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor.
    Dingemanse J; Kneer J; Fotteler B; Groen H; Peeters PA; Jonkman JH
    J Clin Psychopharmacol; 1995 Feb; 15(1):41-8. PubMed ID: 7714227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
    Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
    Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of the pressor effect of intravenously administered tyramine during moclobemide treatment.
    Zimmer R; Fischbach R; Breuel HP
    Acta Psychiatr Scand Suppl; 1990; 360():76-7. PubMed ID: 2248082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.
    Chiuccariello L; Cooke RG; Miler L; Levitan RD; Baker GB; Kish SJ; Kolla NJ; Rusjan PM; Houle S; Wilson AA; Meyer JH
    Int J Neuropsychopharmacol; 2015 Aug; 19(1):. PubMed ID: 26316187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor.
    Korn A; Da Prada M; Raffesberg W; Allen S; Gasic S
    J Neural Transm Suppl; 1988; 26():57-71. PubMed ID: 3162952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.